Rifaximin (drug) — Competitive Intelligence Brief

Rifaximin (drug) (Rifaximin (drug)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Rifamycin antibiotic. Area: Gastroenterology / Infectious Disease.

marketed Rifamycin antibiotic Bacterial RNA polymerase Gastroenterology / Infectious Disease Small molecule

Target snapshot

Rifaximin (drug) (Rifaximin (drug)) — Państwowy Instytut Medyczny Ministerstwa Spraw Wewnętrznych i Administracji. Rifaximin is a non-absorbed antibiotic that inhibits bacterial RNA polymerase to reduce pathogenic gut bacteria.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Rifaximin (drug) TARGET	Rifaximin (drug)	Państwowy Instytut Medyczny Ministerstwa Spraw Wewnętrznych i Administracji	marketed	Rifamycin antibiotic	Bacterial RNA polymerase
Vancomycin plus Gentamicin plus Rifampin	Vancomycin plus Gentamicin plus Rifampin	Michael E. DeBakey VA Medical Center	marketed	Antibiotic combination	Bacterial cell wall (vancomycin), 30S ribosome (gentamicin), bacterial RNA polymerase (rifampin)
Rifampin/isoniazid FDC	Rifampin/isoniazid FDC	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	marketed	Antituberculous agent (fixed-dose combination)	Bacterial RNA polymerase (rifampin); mycolic acid biosynthesis (isoniazid)
rifampin IV	rifampin IV	University of California, San Francisco	marketed	Rifamycin antibiotic	Bacterial RNA polymerase
Rifampicin alone	Rifampicin alone	Miguel Santín	marketed	Rifamycin antibiotic	Bacterial RNA polymerase β-subunit
Rifampicin Capsules	Rifampicin Capsules	Suzhou Zelgen Biopharmaceuticals Co.,Ltd	marketed	Rifamycin antibiotic	Bacterial RNA polymerase
Rifampin/isoniazid/pyrazinamide/ethambutol FDC	Rifampin/isoniazid/pyrazinamide/ethambutol FDC	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	marketed	Anti-tuberculosis agent (fixed-dose combination)	Bacterial RNA polymerase (rifampin), mycolic acid synthesis (isoniazid), membrane potential/energy metabolism (pyrazinamide), arabinosyl transferase (ethambutol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Rifamycin antibiotic class)

1. Institute of Tropical Medicine, Belgium · 2 drugs in this class
2. National Institute of Allergy and Infectious Diseases (NIAID) · 2 drugs in this class
3. National Taiwan University Hospital · 2 drugs in this class
4. Bausch Health Americas, Inc. · 2 drugs in this class
5. South China Children's Leukemia Group · 1 drug in this class
6. Suzhou Zelgen Biopharmaceuticals Co.,Ltd · 1 drug in this class
7. TenNor Therapeutics (Suzhou) Limited · 1 drug in this class
8. The University of Texas Health Science Center at Tyler · 1 drug in this class
9. University College, London · 1 drug in this class
10. University of California, San Francisco · 1 drug in this class